The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Continuous Manufacturing Equipment Providers Market: Distribution by Type of Molecule (Small Molecule and Biologics), Type of Equipment (Mixers, Granulators, Dryers, Bioreactors / Reactors and Others), Stage of Manufacturing (Upstream Process and Downstream Process), Scale of Manufacturing (Preclinical / Clinical and Commercial) and Geography (North America, Europe and Asia Pacific): Industry Trends and Global Forecast, 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    March 2021

  • Pages
    197

  • View Count
    2691

Example Insights

Continuous-Manufacturing-Equipment-Providers-Market-Context Continuous-Manufacturing-Equipment-Providers-Market-Equipment-Providers Continuous-Manufacturing-Equipment-Providers-Market-Distribution-by-Company-Size
Continuous-Manufacturing-Equipment-Providers-Market-Patent Analysis Continuous-Manufacturing-Equipment-Providers-Market-Company-Competitiveness-Analysis Continuous-Manufacturing-Equipment-Providers-Market-Operations
Continuous-Manufacturing-Equipment-Providers-Market-Distribution-by-Type-of-Molecule    

Overview

Pharmaceutical manufacturing processes are complex, time consuming, as well as cost intensive. In fact, it is estimated that production inefficiencies and product recalls (owing to manufacturing errors) are responsible for annual losses amounting to around USD 50 billion. Given the ever-increasing demand for pharmacological interventions, and the introduction of new and sophisticated therapeutic modalities, drug substance manufacturers are gradually opting for more advanced manufacturing solutions, such as continuous flow systems. When compared to the conventional batch manufacturing process, the continuous mode of production has been demonstrated to allow significant cost savings (around 40% to 50% of expenditure when using traditional equipment).  According to the USFDA, using the continuous approach, it is even possible for industry stakeholders to significantly abbreviate production time; for instance, a drug that previously required a month to manufacture, can now be produced in a single day. Continuous processing also enables manufacturers to circumvent concerns related to equipment downtime, and use the entire capacity of production lines, while simultaneously testing the quality of products / production intermediates. Moreover, a continuous manufacturing facility requires 70% less area than a plant that is designed for running batch processes; this enables additional savings, in terms of facility operation costs. Further, continuous manufacturing processes can be automated, and the affiliated equipment usually includes a variety of advanced features that offer real-time visibility on various important parameters. Overall, the adoption of continuous flow technologies is believed to possess the potential to notably improve productivity, while minimizing batch-to-batch variability. So far, the US FDA has approved four therapies that were produced using the continuous manufacturing approach. In addition, there are over 20 product candidates that are currently being manufactured via the same approach. 

Considering the various advantages of continuous manufacturing, pharmaceutical developers are gradually becoming more receptive to adopting such solutions. As a matter of fact, the recent surge in demand for pharmaceuticals amidst the COVID-19 pandemic, has served to create a strong case for pharmaceutical companies to develop the means to produce drugs faster. Moreover, the Centre for Drug Evaluation and Research (CDER) and US Biomedical Advanced Research and Development Authority (BRADA), are currently working closely to promote the use of continuous manufacturing for the production of therapeutics for medical emergencies. As a result, several industry stakeholders that are involved in drug development and production, have already made significant investments towards acquiring continuous manufacturing capabilities and the associated expertise. On the other hand, there are several companies that are now offering continuous manufacturing equipment that contain process analytical technologies (PAT) and advanced sensors. Further, many innovators claim to be engaged in improving the continuous manufacturing process, developing advanced variants of currently available processing systems, and optimizing on the cost of such solutions. The aforementioned developments are anticipated to result in an increase in adoption of continuous processing technologies, over the coming years. 

Scope of the Report

The “Continuous Manufacturing Equipment Providers Market by Type of Molecule (Small Molecules and Biologics), Type of Equipment (Mixers, Granulators, Bioreactors / Reactors and Others), Stage of Manufacturing (Upstream and Downstream Process), Scale of Operation (Preclinical / Clinical and Commercial) and Geography (North America, Europe and Asia Pacific), 2021-2030” report offers an elaborate study of the current scenario and future potential of the continuous manufacturing equipment providers market. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of continuous manufacturing equipment for small molecule drugs, along with information on type of equipment, type of manufacturing process (only continuous and batch continuous), stage of manufacturing (upstream process and downstream process), scale of operation (preclinical / clinical and commercial) and type of product (single purpose and multipurpose equipment). In addition, the chapter highlights the analysis of equipment provider(s), based on various parameters, such as year of establishment, company size, location of headquarters and key players. 
  • A detailed assessment of the current market landscape of continuous manufacturing equipment for biologic drugs, providing information on type of equipment, type of manufacturing process (only continuous and batch continuous), stage of manufacturing (upstream process and downstream process) and scale of operation (preclinical / clinical and commercial). In addition, the chapter highlights the distribution of equipment provider(s), based on various parameters, such as year of establishment, company size, location of headquarters and key players.
  • An in-depth analysis of the various patents filed / granted related to continuous manufacturing and affiliated equipment, till 2020, along with information on key parameters, such as publication year, geography, CPC symbols, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of size of intellectual property portfolio). Further, it features a 3-D bubble analysis (based on publication year, patent citation count and extended geographical reach) and a detailed patent valuation analysis.
  • An insightful 4-D representation, highlighting the competitiveness analysis of continuous manufacturing equipment providers for small molecules and biologics, across key geographical areas, taking into consideration the company experience (experience of the company), product expertise (scale of operation, type of manufacturing process, types of equipment and type of product), product portfolio (number of equipment) and company size (small, mid-sized and large companies).
  • A case study highlighting the contract manufacturing organizations that claim to have the required expertise and capabilities related to continuous manufacturing, along with information on relevant parameters, such as year of establishment, company size, purpose of manufacturing (in-house and contract service), scale of operation (preclinical, clinical and commercial), type of drug molecule, location of headquarters and location of continuous manufacturing facilities.
  • Tabulated profiles of key companies (shortlisted based on number of equipment provided) providing continuous manufacturing equipment for small molecules and biologics manufacturing. Each profile provides an overview of the company, list of continuous manufacturing equipment, financial information (if available), and details on recent developments as well as an informed future outlook. 

One of the key objectives of the report was to estimate the existing market size and future potential of the continuous manufacturing equipment providers market over the coming years. We have provided an informed estimate to the likely evolution of the market in the short to mid-term and long term, for the period of 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented based on [A] type of molecule (small molecule and biologic), [B] type of equipment (mixers, granulators, bioreactors / reactors and others), [C] scale of operation (preclinical / clinical and commercial), stage of manufacturing (upstream and downstream process) and [D] geography (North America, Europe and Asia Pacific).

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Andrea Adamo (Founder and Chief Executive Officer, Zaiput Flow Technologies)
  • Bayan Takizawa (Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals)
  • Graeme Cruickshank (Chief Technology and Innovation Officer, Center for Process Innovation)
  • Nick Thomson (Senior Director Chemical Research and Development, Pfizer)
  • Anonymous (Senior Manager, Continuous Manufacturing Business Development, Patheon)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key players engaged in offering continuous manufacturing equipment for small molecule and biologic drugs?
  • What are the current regulatory requirements for continuous manufacturing, across different geographies?
  • How is the intellectual property landscape likely to evolve in the foreseen future?
  • What factors are likely to influence the evolution of the continuous manufacturing equipment providers market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of continuous manufacturing equipment providers market and its likely evolution in the short-mid and long term.

Chapter 3 is an introductory chapter that highlights important concepts related to continuous manufacturing, including a discussion on the emergence of continuous equipment and technologies, and type of continuous manufacturing equipment presently available in the market. It further elaborates on the advantages offered by the continuous manufacturing technique, key quality / cGMP considerations, challenges associated with continuous manufacturing equipment, overview of existing regulatory guidelines and the future perspectives related to continuous manufacturing equipment.

Chapter 4 includes information on close to 380 continuous manufacturing equipment for small molecule drugs. It features a detailed analysis on type of equipment, type of manufacturing process (only continuous and batch-continuous) and stage of manufacturing (upstream process and downstream process). The chapter also features scale of operation (preclinical / clinical and commercial) and type of product (multipurpose and single purpose). Further, the chapter provides information on equipment provider(s), highlighting their year of establishment, company size, location of headquarters and key players in this domain.

Chapter 5 includes information on more than 80 continuous manufacturing equipment for biologics. It features a detailed analysis on type of equipment, type of manufacturing process (only continuous and batch-continuous) and stage of manufacturing (upstream process and downstream process). The chapter also features analysis on the scale of operation (preclinical / clinical and commercial). Further, the chapter provides information on equipment provider(s) along with information on year of establishment, company size, location of headquarters and key players in this domain.

Chapter 6 features tabulated profiles of key companies (shortlisted based on maximum number of equipment provided) providing continuous manufacturing equipment for small molecule drugs. Each profile provides an overview of the company, list of continuous manufacturing equipment, financial information (if available), and details on recent developments as well as an informed future outlook.

Chapter 7 features tabulated profiles of key companies (shortlisted based on maximum number of equipment provided) providing continuous manufacturing equipment for biologic drugs. Each profile provides an overview of the company, list of continuous manufacturing equipment, financial information (if available), and details on recent developments as well as an informed future outlook.

Chapter 8 presents an in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing and affiliated equipment till 2020. It includes information on key parameters such as their publication year, geographical location, CPC symbol, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of size of intellectual property portfolio). It also features a 3-D bubble analysis (based on publication year, patent citation count and extended geographical reach) and a detailed valuation analysis.

Chapter 9 features a chapter on an insightful 4-D representation, highlighting the competitiveness analysis of continuous manufacturing equipment providers for small molecules and biologics across key geographical areas, taking into consideration company experience (experience of the company), product expertise (scale of operation, type of manufacturing process, types of equipment and type of product), product portfolio (number of equipment) and company size (small, mid-sized and large companies).

Chapter 10 presents a case study on the contract manufacturing organizations having the required expertise and capabilities for continuous manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, purpose of manufacturing (in-house and contract service), scale of operation (preclinical, clinical and commercial), location of headquarter, location of continuous manufacturing facilities and type of drug molecule.

Chapter 11 presents a comprehensive market forecast analysis, highlighting the likely growth of continuous manufacturing equipment providers market, 2021 - 2030. The chapter provides likely distribution of the projected future opportunity based on type of molecule (small molecule and biologic), type of equipment (mixers, granulators, bioreactors / reactors and others), scale of operation (preclinical / clinical and commercial), stage of manufacturing (upstream and downstream process) and geography (North America, Europe and Asia Pacific).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers an independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 14 is a collection of executive insights of the discussion that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interview held with Andrea Adamo (Founder and Chief Executive Officer, Zaiput Flow Technologies), Bayan Takizawa (Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals), Graeme Cruickshank (Chief Technology and Innovation Officer, Center for Process Innovation), Nick Thomson (Senior Director Chemical Research and Development, Pfizer) and Anonymous (Senior Manager, Continuous Manufacturing Business Development, Patheon Pharma Services).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which consists the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview 
3.2. Continuous Manufacturing and Affiliated Technologies
3.3. Types of Continuous Manufacturing Equipment
3.4. Advantages of Continuous Manufacturing
3.5. Quality (cGMP) Considerations
3.6. Challenges Associated with Continuous Manufacturing Equipment
3.7. Future Perspectives

4. CONTINUOUS MANUFACTURING EQUIPMENT FOR SMALL MOLECULE DRUGS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Continuous Manufacturing Equipment for Small Molecule Drugs: Overall Market Landscape
4.2.1. Analysis by Type of Equipment
4.2.2. Analysis by Type of Manufacturing Process
4.2.3. Analysis by Stage of Manufacturing
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Type of Product

4.3. Continuous Manufacturing Equipment for Small Molecule Drugs: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Key Continuous Manufacturing Equipment Providers

5. CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGIC DRUGS: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Continuous Manufacturing Equipment for Biologic Drugs: Overall Market Landscape
5.2.1. Analysis by Type of Equipment
5.2.2. Analysis by Type of Manufacturing Process
5.2.3. Analysis by Stage of Manufacturing
5.2.4. Analysis by Scale of Operation

5.3. Continuous Manufacturing Equipment for Biologic Drugs: Developer Landscape
5.3.1. Analysis by Year oaf Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Key Continuous Manufacturing Equipment Providers

6. CONTINUOUS MANUFACTURING EQUIPMENT FOR SMALL MOLECULE DRUGS: COMPANY PROFILES
6.1. Chapter Overview
6.2 Corning
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook

6.3. Glatt
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook

6.4. IKA
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook

6.5. Kilburn Engineering
6.5.1. Company Overview
6.5.2. Recent Developments and Future Outlook

6.6. Thermo Fisher Scientific
6.6.1. Company Overview
6.6.2. Recent Developments and Future Outlook

7. CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGIC DRUGS: COMPANY PROFILES
7.1. Chapter Overview
7.2. Eppendorf
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook

7.3. Merck Millipore
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook

7.4. Pall
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook

7.5. Sartorius
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook

7.6. TA Instruments
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Continuous Manufacturing Technologies: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Geography
8.3.3. Analysis by CPC Symbols
8.3.4. Emerging Focus Areas
8.3.5. Analysis by Type of Applicant
8.3.6. Leading Players: Analysis by Number of Patents
8.3.7. Analysis by Patent Publication Year, Patent Citation Count and Extended Family Size
8.3.8. Patent Valuation Analysis by Patent Age, Number of Citation and Geographical Reach
8.3.8.1. Leading Patents: Information by Number of Citations

9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Key Parameters
9.3. Continuous Manufacturing Equipment Providers for Small Molecule Drugs
9.3.1. Companies based in North America
9.3.2. Companies based in Europe
9.3.3. Companies based in Asia Pacific
9.3.4. Key Players: Analysis by Company Experience, Product Expertise, Product Portfolio and Key Market Presence

9.4. Continuous Manufacturing Equipment Providers for Biologic Drugs
9.4.1. Companies based in North America
9.4.2. Companies based in Rest of the World (Europe and Asia Pacific)
9.4.3. Key Players: Analysis by Company Experience, Product Expertise, Product Portfolio and Key Market Presence

10. CASE STUDY: COMPANIES WITH EXPERTISE IN CONTINUOUS MANUFACTURING
10.1. Context and Background
10.2. Early Adopters of Continuous Manufacturing
10.3. Companies with Expertise in Continuous Manufacturing
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Purpose of Manufacturing
10.3.4. Analysis by Scale of Operation
10.3.5. Analysis by Type of Drug Molecule
10.3.6. Analysis by Location of Headquarters
10.3.7. Analysis by Year of Establishment and Company Size (Logo Landscape)
10.3.8. Analysis by Location of Continuous Drug Manufacturing Facilities
10.4. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Forecast Methodology
11.3. Global Continuous Manufacturing Equipment Providers Market, 2021-2030
11.4. Continuous Manufacturing Equipment Providers Market, 2021-2030: Distribution by Type of Molecule
11.4.1. Continuous Manufacturing Equipment Providers Market for Small Molecule Drugs, 2021-2030
11.4.2. Continuous Manufacturing Equipment Providers Market for Biologics, 2021-2030

11.5. Continuous Manufacturing Equipment Providers Market, 2021-2030: Distribution by Type of Equipment
11.5.1. Continuous Manufacturing Equipment Providers Market for Mixers, 2021-2030
11.5.2. Continuous Manufacturing Equipment Providers Market for Granulators, 2021-2030
11.5.3. Continuous Manufacturing Equipment Providers Market for Dryers, 2021-2030
11.5.4. Continuous Manufacturing Equipment Providers Market for Bioreactors / Reactors, 2021-2030
11.5.5. Continuous Manufacturing Equipment Providers Market for Other Equipment, 22021-2030

11.6. Continuous Manufacturing Equipment Providers Market, 2021-2030: Distribution by Type of Manufacturing Process
11.6.1. Continuous Manufacturing Equipment Providers Market for Upstream Process, 2021-2030
11.6.2. Continuous Manufacturing Equipment Providers Market for Downstream Process, 2021-2030

11.7. Continuous Manufacturing Equipment Providers Market, 2021-2030: Distribution by Scale of Operation
11.7.1. Continuous Manufacturing Equipment Providers Market for Preclinical / Clinical Scale Operations, 2021-2030
11.7.2. Continuous Manufacturing Equipment Providers Market for Commercial Scale Operations, 2021-2030

11.8. Continuous Manufacturing Equipment Providers Market, 2021-2030: Distribution by Type of Geography
11.8.1. Continuous Manufacturing Equipment Providers Market in North America, 2021-2030
11.8.2. Continuous Manufacturing Equipment Providers Market in Europe, 2021-2030
11.8.3. Continuous Manufacturing Equipment Providers Market in Asia Pacific, 2021-2030

12. CONCLUDING REMARKS
12.1. Chapter Overview
12.2. Key Takeaway

13. INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. Andrea Adamo, Founder and Chief Executive Officer, Zaiput Flow Technologies
13.3. Bayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals
13.4. Graeme Cruickshank, Chief Technology and Innovation Officer, Centre for Process Innovation
13.5. Nick Thomson, Senior Director Chemical Research and Development, Pfizer
13.6. Anonymous, Senior Manager, Continuous Manufacturing Business Development, Patheon

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Comparison between Batch and Integrated Continuous Manufacturing Processes
Figure 3.2 Types of Continuous Manufacturing Equipment
Figure 4.1 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Equipment
Figure 4.2 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Manufacturing Process
Figure 4.3 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Stage of Manufacturing
Figure 4.4 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Scale of Operation
Figure 4.5 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Product
Figure 4.6 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Year of Establishment
Figure 4.7 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Company Size
Figure 4.8 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Location of Headquarters
Figure 4.9 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Key Players
Figure 5.1 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
Figure 5.2 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
Figure 5.3 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Manufacturing
Figure 5.4 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
Figure 5.5 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
Figure 5.6 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
Figure 5.7 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
Figure 5.8 Continuous Manufacturing Equipment Providers for Biologic Drugs: Key Players
Figure 8.1 Patent Analysis: Distribution by Type of Patent
Figure 8.2 Patent Analysis: Cumulative Year-wise Trend
Figure 8.3 Patent Analysis: Distribution by Region
Figure 8.4 Patent Analysis: Distribution by CPC Symbols
Figure 8.5 Patent Analysis: Distribution of CPC Symbols by Publication Year
Figure 8.6 Patent Analysis: Emerging Focus Areas
Figure 8.7 Patent Analysis: Distribution by Type of Applicant
Figure 8.8 Leading Industry Players: Distribution by Number of Patents
Figure 8.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.10 3-D Bubble Analysis: Distribution by Publication Year, Citation Count and Extended Geographical Family
Figure 8.11 Patent Analysis: Distribution by Patent Age, 2000- 2020 (till November)
Figure 8.12 Patent Analysis: Distribution by Region, Pre 2014 – 2020 (till November)
Figure 8.13 Continuous Manufacturing Technologies for Pharmaceuticals: Patent Valuation
Figure 9.1 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in North America
Figure 9.2 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in Europe
Figure 9.3 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in Asia Pacific
Figure 9.4 Continuous Manufacturing Equipment Providers for Small Molecules: Key Players
Figure 9.5 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Biologics in North America
Figure 9.6 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Biologics in RoW
Figure 9.7 Continuous Manufacturing Equipment Providers for Biologics: Key Players
Figure 10.1 Continuous Drug Manufacturers: Distribution by Year of Establishment
Figure 10.2 Continuous Drug Manufacturers: Distribution by Company Size
Figure 10.3 Continuous Drug Manufacturers: Distribution by Purpose of Manufacturing
Figure 10.4 Continuous Drug Manufacturers: Distribution by Scale of Operation
Figure 10.5 Continuous Drug Manufacturers: Distribution by Location of Headquarters
Figure 10.6 Continuous Drug Manufacturers: Distribution by Year of Establishment and Company Size
Figure 10.7 Continuous Drug Manufacturers: Distribution by Location of Facilities
Figure 10.8 Continuous Drug Manufacturers: Distribution by Type of Drug
Figure 12.1 Global Continuous Manufacturing Equipment Providers Market, 2021-2030
Figure 12.2 Global Continuous Manufacturing Equipment Providers Market for Small Molecules, 2021-2030
Figure 12.3 Global Continuous Manufacturing Equipment Providers Market for Biologics, 2021-2030
Figure 12.4 Continuous Manufacturing Equipment Providers Market for Mixers, 2021-2030
Figure 12.5 Continuous Manufacturing Equipment Providers Market for Granulators, 2021-2030
Figure 12.6 Continuous Manufacturing Equipment Providers Market for Dryers, 2021-2030
Figure 12.7 Continuous Manufacturing Equipment Providers Market for Bioreactors / Reactors, 2021-2030
Figure 12.8 Continuous Manufacturing Equipment Providers Market for Other Equipment, 2021-2030
Figure 12.9 Continuous Manufacturing Equipment Providers Market for Upstream Process, 2021-2030
Figure 12.10 Continuous Manufacturing Equipment Providers Marker for Downstream Process, 2021-2030
Figure 12.11 Continuous Manufacturing Equipment Providers Market for Preclinical / Clinical Operations, 2021-2030
Figure 12.12 Continuous Manufacturing Equipment Providers Market for Commercial Operations, 2021-2030
Figure 12.13 Continuous Manufacturing Equipment Providers Market in North America, 2021-2030
Figure 12.14 Continuous Manufacturing Equipment Providers Market in Europe, 2021-2030
Figure 12.15 Continuous Manufacturing Equipment Providers Market in Asia Pacific, 2021-2030

List Of Tables

Table 3.1 Batch versus Continuous Manufacturing Technology: Comparison of Key Characteristics
Table 4.1 Continuous Manufacturing Equipment for Small Molecules: Information on Type of Equipment, Type of Manufacturing Process and Stage of Manufacturing
Table 4.2 Continuous Manufacturing Equipment for Small Molecules: Information on Scale of Operation, Type of Product and Throughput / Capacity
Table 4.3 Continuous Manufacturing Equipment Providers for Small Molecules: Information of Year of Establishment, Company Size and Location of Headquarters
Table 5.1 Continuous Manufacturing Equipment for Biologics: Information on Type of Equipment, Type of Manufacturing Process and Stage of Manufacturing
Table 5.2 Continuous Manufacturing Equipment for Biologics: Information on Scale of Operation and Throughput / Capacity
Table 5.3 Continuous Manufacturing Equipment Providers for Biologics: Information of Year of Establishment, Company Size and Location of Headquarters
Table 6.1 Corning: Company Snapshot
Table 6.2 Corning: Recent Developments and Future Outlook
Table 6.3 Glatt: Company Snapshot
Table 6.4 Glatt: Recent Developments and Future Outlook
Table 6.5 IKA: Company Snapshot
Table 6.6 Kilburn Engineering: Company Snapshot
Table 6.7 Thermo Fisher Scientific: Company Snapshot
Table 6.8 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 7.1 Eppendorf: Company Snapshot
Table 7.2 Eppendorf: Recent Developments and Future Outlook
Table 7.3 Merck Millipore: Company Snapshot
Table 7.4 Merck Millipore: Recent Developments and Future Outlook
Table 7.5 Pall: Company Snapshot
Table 7.6 Pall: Recent Developments and Future Outlook
Table 7.7 Sartorius: Company Snapshot
Table 7.8 Sartorius: Recent Developments and Future Outlook
Table 7.9 TA Instruments: Company Snapshot
Table 7.10 TA Instruments: Recent Developments and Future Outlook
Table 8.1 Patent Analysis: Prominent CPC Symbols
Table 8.2 Patent Analysis: Most Popular CPC Symbols
Table 8.3 Patent Analysis: Top CPC Symbols
Table 8.4 Patent Valuation Analysis: Categorization based on Proprietary Scoring Criteria
Table 8.5 Patent Analysis: Distribution by Number of Citations
Table 10.1 Continuous Drug Manufacturers: Information on Year of Establishment, Company Size, Purpose of Manufacturing, Scale of Operation and Location of Headquarters
Table 10.2 Continuous Drug Manufacturers: Information on Number and Location of Production Facilities
Table 10.3 Continuous Drug Manufacturers: Information on Type of Drug Manufactured
Table 13.1 Zaiput Flow Technologies: Company Snapshot
Table 13.2 CONTINUUS Pharmaceuticals: Company Snapshot
Table 13.3 Centre for Process Innovation: Company Snapshot
Table 13.4 Pfizer: Company Snapshot
Table 13.5 Patheon: Company Snapshot
Table 14.1 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Equipment
Table 14.2 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Manufacturing Process
Table 14.3 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Stage of Manufacturing
Table 14.4 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Scale of Operation
Table 14.5 Continuous Manufacturing Equipment for Small Molecule Drugs: Distribution by Type of Product
Table 14.6 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Year of Establishment
Table 14.7 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Company Size
Table 14.8 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Distribution by Location of Headquarters
Table 14.9 Continuous Manufacturing Equipment Providers for Small Molecule Drugs: Key Players
Table 14.10 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
Table 14.11 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
Table 14.12 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Manufacturing
Table 14.13 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
Table 14.14 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
Table 14.15 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
Table 14.16 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
Table 14.17 Continuous Manufacturing Equipment Providers for Biologic Drugs: Key Players
Table 14.18 Patent Analysis: Distribution by Type of Patent
Table 14.19 Patent Analysis: Cumulative Year-wise Trend
Table 14.20 Patent Analysis: Distribution by Geographical Region
Table 14.21 Patent Analysis: Distribution by CPC Symbols
Table 14.22 Patent Analysis: Distribution of CPC Symbols by Publication Year
Table 14.23 Patent Analysis: Emerging Focus Areas
Table 14.24 Patent Analysis: Distribution by Type of Applicant
Table 14.25 Leading Industry Players: Distribution by Number of Patents
Table 14.26 Leading Non-Industry Players: Distribution by Number of Patents
Table 14.27 3-D Bubble Analysis: Distribution by Publication Year, Citation Count and Extended Geographical Family
Table 14.28 Patent Analysis: Distribution by Patent Age, 2000- 2020 (till November)
Table 14.29 Patent Analysis: Distribution by Region, Pre 2014 – 2020 (till November)
Table 14.30 Continuous Manufacturing Technologies for Pharmaceuticals: Patent Valuation
Table 14.31 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in North America
Table 14.32 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in Europe
Table 14.33 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Small Molecules in Asia Pacific
Table 14.34 Continuous Manufacturing Equipment Providers for Small Molecules: Key Players
Table 14.35 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Biologics in North America
Table 14.36 Company Competitiveness Analysis: Continuous Manufacturing Equipment Providers for Biologics in RoW
Table 14.37 Continuous Manufacturing Equipment Providers for Biologics: Key Players
Table 14.38 Continuous Drug Manufacturers: Distribution by Year of Establishment
Table 14.39 Continuous Drug Manufacturers: Distribution by Company Size
Table 14.40 Continuous Drug Manufacturers: Distribution by Purpose of Manufacturing
Table 14.41 Continuous Drug Manufacturers: Distribution by Scale of Operation
Table 14.42 Continuous Drug Manufacturers: Distribution by Location of Headquarters
Table 14.43 Continuous Drug Manufacturers: Distribution by Year of Establishment and Company Size
Table 14.44 Continuous Drug Manufacturers: Distribution by Location of Facilities
Table 14.45 Continuous Drug Manufacturers: Distribution by Type of Drug
Table 14.46 Global Continuous Manufacturing Equipment Providers Market, 2021-2030
Table 14.47 Global Continuous Manufacturing Equipment Providers Market for Small Molecules, 2021-2030
Table 14.48 Global Continuous Manufacturing Equipment Providers Market for Biologics, 2021-2030
Table 14.49 Continuous Manufacturing Equipment Providers Market for Mixers, 2021-2030
Table 14.50 Continuous Manufacturing Equipment Providers Market for Granulators, 2021-2030
Table 14.51 Continuous Manufacturing Equipment Providers Market for Dryers, 2021-2030
Table 14.51 Continuous Manufacturing Equipment Providers Market for Bioreactors / Reactors, 2021-2030
Table 14.52 Continuous Manufacturing Equipment Providers Market for Other Equipment, 2021-2030
Table 14.53 Continuous Manufacturing Equipment Providers Market for Upstream Process, 2021-2030
Table 14.54 Continuous Manufacturing Equipment Providers Marker for Downstream Process, 2021-2030
Table 14.55 Continuous Manufacturing Equipment Providers Market for Preclinical / Clinical Operations, 2021-2030
Table 14.56 Continuous Manufacturing Equipment Providers Market for Commercial Operations, 2021-2030
Table 14.57 Continuous Manufacturing Equipment Providers Market in North America, 2021-2030
Table 14.58 Continuous Manufacturing Equipment Providers Market in Europe, 2021-2030
Table 14.59 Continuous Manufacturing Equipment Providers Market in Asia Pacific, 2021-2030

List Of Companies

The following companies and organizations have been included in the report.

  1. 3D Biotek
  2. AbbVie
  3. Ajax Equipment
  4. Alexanderwerk
  5. Allgaier Process Technology
  6. Amgen
  7. amixon
  8. Applikon Biotechnology
  9. AstraZeneca
  10. AWL (Alconbury Weston Limited)
  11. Baker Perkins
  12. bbi-biotech
  13. Boeing
  14. Cell Culture Company
  15. Cellec Biotek 
  16. Centre for Process Innovation
  17. Changzhou Ruide Drying Engineering Technology
  18. Chemtrix
  19. Commonwealth Scientific and Industrial Research Organization
  20. CONTINUUS Pharmaceuticals
  21. Coperion
  22. Corning
  23. Cytiva
  24. DCI-Biolafitte
  25. Design Integrated Technology
  26. DEVEX Verfahrenstechnik
  27. DRIAM 
  28. Eli Lilly
  29. Eppendorf
  30. Evaporators & Dryers Engineering 
  31. Florida State University
  32. Freund
  33. GEA
  34. Gericke
  35. Gilead Sciences
  36. Glatt
  37. Hosokawa Micron Powder Systems
  38. Hovione
  39. IKA
  40. Iowa Mixing and Process Equipment Company
  41. Janssen
  42. Jaygo 
  43. Kemutec 
  44. Kevin Process Technologies
  45. Kilburn Engineering
  46. KORSCH
  47. Kurimoto
  48. L.B. Bohle
  49. LCI
  50. Lödige Process Technology
  51. Massachusetts Institute of Technology
  52. Merck
  53. Metso
  54. Munson Machinery
  55. Neuhaus Neotec
  56. NiTech Solutions
  57. Novartis
  58. E.T. Oakes
  59. O'Hara Technologies
  60. OmniBRx Biotechnologies
  61. Pall Life Sciences
  62. Patheon
  63. Pfizer
  64. Pierre Guerin
  65. Proton Engineers
  66. Purdue University
  67. Puschner
  68. Readco Kurimoto
  69. Repligen
  70. Riera Nadeu
  71. Shuanglong Group
  72. S. Howes
  73. SaintyCo
  74. Saka Engineering Systems
  75. Sartorius
  76. Scott Equipment Company
  77. Semba Biosciences
  78. Senieer
  79. Shachi Engineering 
  80. Shree Bhagwati Machtech
  81. Buss-SMS-Canzler
  82. Sonic 
  83. SPX FLOW
  84. Stalam
  85. STEERLife
  86. Sturtevant
  87. symex
  88. Syntegon
  89. Synthecon
  90. TA Instruments
  91. Tema Process
  92. The Young Industries
  93. Thermo Fisher Scientific
  94. Thomas
  95. Uni-Mech Industries
  96. University of California
  97. University of Illinois
  98. Vapourtec
  99. Vertex
  100. XPure
  101. Yenchen Machinery 
  102. YMC Process Technologies
  103. Zaiput Flow Technologies

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com